Dave Marriott Named to The Daily Journal’s 2024 List of “Leading Commercial Litigators”
January 31, 2024
On January 24, 2024, Cravath partner David R. Marriott was named to the Daily Journal’s 2024 list of “Leading Commercial Litigators.” The accompanying profile highlights his role in helping Amgen secure a consent order ending all litigation in connection with its pending acquisition of Horizon Therapeutics, as well as his summary judgment victory for Viatris, which was “one of the few resolutions of federal securities fraud litigation at summary judgment that ended entirely in favor of the defendants.” The profile also details Dave’s nearly 30‑year tenure at Cravath and his roles as a lecturer at Columbia University Law School and an adjunct professor at NYU School of Law.
Related Practices & Industries
People
- Photo
-
-
J.D., 1994, New York University School of Law
-
B.A., 1991, Brigham Young Universitymagna cum laude
- New York
Education
Admitted In
Related News
Deals & Cases
September 11, 2023
Amgen Successfully Defends Against FTC Challenge, Securing Clearance for its $27.8 Billion Acquisition of Horizon Therapeutics
Cravath represented Amgen, one of the world’s largest biopharmaceutical companies, in successfully defending against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that The Wall Street Journal described as “a rare instance” of the FTC “throwing in the towel on litigation.”
Deals & Cases
April 07, 2023
Viatris Wins Summary Judgment in Securities Class Action
On Thursday, March 30, 2023, the U.S. District Court for the Southern District of New York granted summary judgment in favor of Cravath client Viatris (formed in 2020 from a combination of Mylan and Pfizer’s Upjohn division). The shareholder class action asserted numerous violations of the federal securities laws, all premised on other allegations related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.
